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 Schizophrenia is a mental illness affecting millions of people worldwide and is characterised by “fundamental 
and characteristic distortions of thinking and perception” (ICD)1.  The international diagnostic criteria classify 
schizophrenia as a non-organic disorder, at the same clinicians continue to use "organic" in day-to-day practice 
to refer to non-“functional” causes of psychosis and vice versa.  This is despite mounting evidence to the 
contrary and has important implications for our treatment of patients with schizophrenia and resource allocation.   
 
In the medical context, the term organic is generally taken to mean an illness in which there is change in the 
structure or function of an organ.  In addition, the ICD-10 describes several criteria to differentiate between non-
organic and organic disorders (table).   
  
 Table: Supporting criteria for making diagnosis of an organic mental disorder (ICD-10) 
ICD-10 Criteria supporting a diagnosis of organic 
disorder1 
Key findings in schizophrenia 
Evidence of cerebral disease, damage or dysfunction. 
 
Increase in lateral ventricle size2. 
Reduced cross-sectional area of the corpus callosum3. 
Reduced volumes of the temporal structures3. 
Reduced fronto-temporal white matter connectivity4 . 
Elevated microglial cell density post mortem5 and microglial activation 
in vivo6.  
Neurochemical dysfunction including elevated striatal dopamine 
synthesis capacity7. 
A temporal relationship between the development of the 
underlying disease and the onset of the mental syndrome 
There is a temporal relationship between the development of structural8 
and neurochemical abnormalities7 and the onset of psychosis . 
Recovery from the mental disorder following removal or 
improvement of the underlying presumed cause 
Schizophrenia is associated with raised striatal dopamine synthesis and 
release capacity7 and symptoms of schizophrenia improve when this is 
blocked with dopamine antagonists.    
Absence of evidence to suggest an alternative cause of the 
mental syndrome such as a strong family history or 
precipitating stress.  
This criterion is not appropriate.  “Organic” illnesses can be hereditary 
or contributed to by stress (e.g.  hypertension).  
 
The organic nature of schizophrenia has long been hypothesised.  A century ago Emile Kraepelin suggested that 
we would one day be able to elucidate the neuropathology of dementia praecox (what we would now call 
schizophrenia).9 It took some time to develop the tools to investigate this in vivo, but many studies have now 
tested this. 
 
In 1976 Johnstone et al.2 were the first to demonstrate, using computed tomography (CT), that patients with 
schizophrenia have increased lateral cerebral ventricle size. These results have since been replicated multiple 
times and further evidence of additional structural brain changes have been consistently found3.  Moreover, 
brain imaging shows promise in the differential diagnosis of schizophrenia and mood disorders10. Structural 
changes have also been shown to pre-exist the first episode of psychosis, leading to the hypothesis that 
schizophrenia is a neurodevelopmental disorder8,11. Additionally, a meta-analysis using diffusion tensor imaging 
(DTI) has shown reduction in connectivity of two separate networks of white matter tracts, hence disconnection 
between grey matter regions4.  This provides an organic basis for the functional dysconnectivity, i.e. abnormal 
connections, observed clinically in terms of symptomatology and experimentally, across a range of measures, in 
schizophrenia.   
 
Furthermore, a classically described marker of an organic disease process is the presence of inflammation.  Post-
mortem studies have shown evidence of elevated microglial cell density in the brains of patients with 
schizophrenia, particularly in the frontal and temporal lobes5, and there is recent in vivo evidence supporting 
these findings in participants at ultra-high-risk of developing psychosis6.  These findings pre-date the onset of 
frank psychosis, suggesting causal association of the inflammatory activity and psychosis, and hence organic 
pathology.  
 
 
In view of all this evidence, the fundamental criteria for organicity are either met in schizophrenia, or appear 
questionable (table).   We can no longer divide illness into organic and inorganic based on the technological 
limitations of late 19th Century anatomy and histology.  Moreover, the current classification implies that there is 
a non-organic aetiology to schizophrenia, and by extension that this should direct management. Whilst it is clear 
that psychological and social factors play a major role in the illness, no psychological or social mechanism has 
been established as solely underlying the disorder or present in all cases, just as is the case for biological 
factors11. Instead, in most patients, a combination of psychological, social and biological factors play a role in 
the illness and its treatment, just as is the case with other common medical conditions such as diabetes mellitus.   
 
 
The current classification of schizophrenia as a non-organic illness influences service organisation and resource 
allocations. Mental health services continue to be mostly separate from the rest of medical services, with distinct 
hospitals, teams and management. Moreover, in many countries, per capita spending on healthcare for patients 
with psychiatric illnesses is below that for non-psychiatric disorders.  Already within an under-resourced sector, 
in the English National Health Service mental illnesses are further categorised into “non-psychotic”, “psychotic” 
and “organic” illnesses for the purposes of resource allocation.  This out-dated and trichotomous categorisation 
continues to be used in clinical decision-making and the commissioning and payment of services whereby 
patients are “clustered” and receive a “package of care” with a set tariff based on which category they fall in 
rather than healthcare need 
(https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/300864/Guidance_to_mental_he
alth_currencies_and_payment.pdf).  A patient with an “organic” illness attracts a higher care cluster and 
different payment tariff irrespective of actual needs. Despite decades of research indicating that this 
categorisation is inappropriate it continues to dominate resource allocation, with negative consequences for 
patients.  
  
  
 
The suggestion of a non-organic aetiology of mental illness also has an impact on its perception by the public 
and the rest of the medical profession. Despite psychiatry being a medical speciality, patients with schizophrenia 
are referred to psychiatrists from other specialists with comments in their clinical notes including that they are 
“medically fit” and have “no evidence of organic illness”.  This perpetuates a Cartesian dualistic fallacy that 
schizophrenia, and by extension other psychiatric illnesses, are quasi-illnesses that do not require the full range 
of healthcare available.  Despite mental illnesses contributing a growing proportion of the disease burden, 
spending accounts for comparatively small proportions of clinical care, public health and medical research.  For 
example, every year the UK Government invests approximately £61 per patient affected in research into 
psychotic illnesses, compared to £1,571 per patient for cancer12.    
 
Given the evidence for organic involvement in schizophrenia, and the implications of the non-organic 
distinction, it remains unclear why schizophrenia continues to be categorised as a non-organic illness despite 
evidence to the contrary.  Perhaps refusal to accept the accumulated data might offer evidence for another 
clinical construction with its roots in the 19th century: the psychoanalytic concept of denial?   
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